Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

[99mTc]Tc-HYNIC-FAPI

Phase 1

TTomsk National Research Medical Center of the Russian Academy of Sciences

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lung Cancer (locally Advanced or Metastatic)Active, not recruiting

Lung Cancer (locally Advanced or Metastatic)Phase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Lung Cancer (locally Advanced or Metastatic)

NCT07457541

Clinical

Trials by Indication[1]

Lung Cancer (Locally Advanced or Metastatic)1 trial

SPECT/CT Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI ([99mTc]Tc- HYNIC-FAPI) in Metastatic Cancer Patients

Active, not recruiting·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 1·NCT07457541·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for [99mTc]Tc-HYNIC-FAPI. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [99mTc]Tc-HYNIC-FAPI. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tomsk National Research Medical Center of the Russian Academy of Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: TTomsk National Research Medical Center of the Russian Academy of Sciences

Related News